ReviewFrontiers in immunology2021
Archaeosomes and Gas Vesicles as Tools for Vaccine Development.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- US Molecular Imaging of Glypican-3 Expression in Hepatocellular Carcinoma Using Targeted Biosynthetic Gas Vesicles.Radiology. Imaging cancer · 2026Article
- Microbial Biotechnology in Medicine.Progress in molecular and subcellular biology · 2026Review
- Natural carrier systems in cancer vaccines and immunotherapy.Human vaccines & immunotherapeutics · 2025Review
- Biotechnological Potential of Extremophiles: Environmental Solutions, Challenges, and Advancements.Biology · 2025Review
- Review
- Advances in the Functionalization of Vaccine Delivery Systems: Innovative Strategies and Translational Perspectives.Pharmaceutics · 2025Review
- Sulfated lactosyl archaeol (SLA) archaeosomes as a vaccine adjuvant.Human vaccines & immunotherapeutics · 2024Review
- Structure Diversity and Properties of Some Bola-like Natural Products.Marine drugs · 2024Review
- Advances in the application of gas vesicles in medical imaging and disease treatment.Journal of biological engineering · 2024Review
- Characterization and Comparison of Contrast Imaging Properties of Naturally Isolated and Heterologously Expressed Gas Vesicles.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Non-Invasive Vaccines: Challenges in Formulation and Vaccine Adjuvants.Pharmaceutics · 2023Review
- Article
- Archaeosomes: New Generation of Liposomes Based on Archaeal Lipids for Drug Delivery and Biomedical Applications.ACS omega · 2023Review
- Modification of PEG reduces the immunogenicity of biosynthetic gas vesicles.Frontiers in bioengineering and biotechnology · 2023Article
- Enhancing the Effect of Nucleic Acid Vaccines in the Treatment of HPV-Related Cancers: An Overview of Delivery Systems.Pathogens (Basel, Switzerland) · 2022Review
- Recent Advances in the Study of Gas Vesicle Proteins and Application of Gas Vesicles in Biomedical Research.Life (Basel, Switzerland) · 2022Review
- Halophilic ArchaeaFrontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Archaea are prokaryotic organisms that were classified as a new domain in 1990. Archaeal cellular components and metabolites have found various applications in the pharmaceutical industry. Some archaeal lipids can be used to produce archaeosomes, a new family of liposomes that exhibit high stability to temperatures, pH and oxidative conditions. Additionally, archaeosomes can be efficient antigen carriers and adjuvants promoting humoral and cellular immune responses. Some archaea produce gas vesicles, which are nanoparticles released by the archaea that increase the buoyancy of the cells and facilitate an upward flotation in water columns. Purified gas vesicles display a great potential for bioengineering, due to their high stability, immunostimulatory properties and uptake across cell membranes. Both archaeosomes and archaeal gas vesicles are attractive tools for the development of novel drug and vaccine carriers to control various diseases. In this review we discuss the current knowledge on production, preparation methods and potential applications of archaeosomes and gas vesicles as carriers for vaccines. We give an overview of the traditional structures of these carriers and their modifications. A comparative analysis of both vaccine delivery systems, including their advantages and limitations of their use, is provided. Gas vesicle- and archaeosome-based vaccines may be powerful next-generation tools for the prevention and treatment of a wide variety of infectious and non-infectious diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.